Revenue
2022
2023
2024
2025
Beta Bionics, Inc. (BBNX)
Price$19.23Cached quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $100.3M | $65.1M | $12.0M | $179,000 |
| Gross profit | $55.5M | $35.9M | $6.3M | $179,000 |
| Gross margin | 55.40% | 55.11% | 52.59% | 100.00% |
| Research & development | $34.8M | $26.2M | $17.9M | $31.4M |
| Operating expenses | $127.2M | $81.1M | $42.2M | $66.0M |
| Operating income | −$71.7M | −$45.3M | −$35.9M | −$65.8M |
| Operating margin | −71.50% | −69.48% | −298.87% | −36,784.36% |
| EBITDA | −$70.1M | −$44.1M | −$34.6M | −$62.6M |
| EBITDA margin | −69.93% | −67.72% | −288.65% | −35,000.00% |
| Net income | −$73.2M | −$54.8M | −$44.1M | −$64.8M |
| Net profit margin | −73.02% | −84.08% | −367.64% | −36,173.74% |
| Basic EPSper basic share | -$1.81 | -$8.60 | -$8.31 | -$2.12 |
| Diluted EPSper diluted share | -$1.81 | -$8.60 | -$8.31 | -$2.12 |
Owners
Reported shareholders
13.90%of listed shares
EVENTIDE ASSET MANAGEMENT, LLC6.25M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
EVENTIDE ASSET MANAGEMENT, LLC | 13.90%6.25M shares |
Soleus Capital Management, L.P. | 9.77%4.39M shares |
MORGAN STANLEY | 9.49%4.27M shares |
Wellington Hadley Harbor Aggregator IV, L.P. | ≈8.67%3.9M shares |
Sands Capital Alternatives, LLC | 8.24%3.71M shares |
BlackRock, Inc. | 7.43%3.34M shares |
Point72 Asset Management, L.P. | 5.01%2.25M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.96%1.78M shares |
Vestal Point Capital, LP | 3.56%1.6M shares |
RTW INVESTMENTS, LP | 3.33%1.5M shares |
DEERFIELD MANAGEMENT COMPANY, L.P. | 2.94%1.32M shares |
Omega Fund Management, LLC | 2.93%1.32M shares |
Eversept Partners, LP | 2.78%1.25M shares |
Divisadero Street Capital Management, LP | 2.48%1.11M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.39%1.07M shares |
STATE STREET CORP | 2.16%970.19K shares |
MILLENNIUM MANAGEMENT LLC | 2.13%956.24K shares |
Balyasny Asset Management L.P. | 1.90%855.68K shares |
PERCEPTIVE ADVISORS LLC | 1.85%832.94K shares |
JPMORGAN CHASE & CO | 1.56%703.36K shares |
Percentages use 44.98M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 29, 2026Form 4 · 10b5-1 | Feider StephenChief Financial Officer | SellCommon Stock | 4.9K | $17.03 | $83.4K | 165.9K |
| Jun 26, 2026Form 4 · 10b5-1 | Feider StephenChief Financial Officer | SellCommon Stock | 5.1K | $17.05 | $87.0K | 165.9K |
| Jun 24, 2026Form 4 · 10b5-1 | Hopman MarkChief Commercial Officer | SellCommon Stock | 1.3K | $15.01 | $18.9K | 129.4K |
| Jun 24, 2026Form 4 · 10b5-1 | Jones ChristyDirector | SellCommon Stock | 1.4K | $15.00 | $21.1K | 26.0K |
| Jun 4, 2026Form 4 · 10b5-1 | Hopman MarkChief Commercial Officer | SellCommon Stock | 275 | $12.31 | $3.4K | 130.6K |
Community posts
Beta Bionics prices $150 million equity and warrant offering
Beta Bionics ($BBNX) priced a public offering expected to raise approximately $150 million before fees and expenses. The financing includes 7,652,175 common shares at $17.25 each and pre-funded warrants covering another 1,043,484 shares. Un ...
